Tovorafenib Suppliers & Bulk Manufacturers
Available Forms: Oral suspension
Available Strengths: 25 mg/ml
Reference Brands: Ojemda (USA)
Category: Oncology Cancer Care
Tovorafenib is available in Oral suspension and strengths such as 25 mg/ml. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Tovorafenib is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Tovorafenib can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
Tovorafenib is an oral targeted therapy used for the treatment of glioma, particularly in patients with tumors driven by abnormal RAF signaling. It is a type II RAF kinase inhibitor designed to selectively block aberrant RAF activity, which plays a critical role in tumor cell growth and survival. By inhibiting this pathway, tovorafenib helps slow disease progression and supports tumor control in affected patients.
Marketed under the brand name Ojemda, tovorafenib is used in oncology care where precise molecular targeting is essential. It has demonstrated clinical benefit in patients with glioma and is administered orally, offering a convenient treatment option compared with invasive therapies. As a targeted agent, tovorafenib requires careful patient selection and monitoring to optimize therapeutic outcomes.
Common adverse reactions associated with tovorafenib therapy include rash, fatigue, hair color changes, headache, nausea, vomiting, dry skin, constipation, fever, and upper respiratory tract infections. Laboratory abnormalities may include changes in phosphate, hemoglobin, liver enzymes, creatinine phosphokinase, electrolytes, and blood cell counts. Due to these effects, routine clinical and laboratory monitoring is recommended during treatment. Tovorafenib represents an important advancement in precision oncology for glioma management.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Tovorafenib is used for the treatment of pediatric patients with relapsed or refractory low-grade glioma (LGG) that have a BRAF alteration, including BRAF fusion or mutation.
Tovorafenib is a small-molecule, selective type II pan-RAF kinase inhibitor designed to target abnormal RAF signaling involved in tumor growth.
The trade name of tovorafenib is Ojemda.
Tovorafenib is developed and marketed by Day One Biopharmaceuticals.
The generic name is tovorafenib.
The brand name is Ojemda.
Tovorafenib is manufactured in GMP-compliant pharmaceutical facilities for commercial supply in the United States.
Related Products
Momelotinib
Strength:
100 mg, 150 mg, 200 mg
Form: Tablets
Reference Brands: Ojjaara (USA)
View Details
Nirogacestat
Strength:
50 mg
Form: Tablets
Reference Brands: Generic formulations marketed under different names
View Details
Nintedanib
Strength:
100 mg, 150 mg
Form: Capsules
Reference Brands: Ofev (USA, EU), Vargatef (EU)
View Details
Quick Response Guaranteed | Verified Suppliers
